Tags

Type your tag names separated by a space and hit enter

Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men.
Int J Obes Relat Metab Disord. 2001 Aug; 25(8):1136-43.IJ

Abstract

OBJECTIVE

The aim of the present study was to investigate the effects of a 6 month gemfibrozil treatment.

SUBJECTS

A sample of 64 visceral obese men (age 46+/-6 y; body mass index 31+/-3 kg/m(2); waist circumference 104+/-7 cm; mean+/-s.d.) who received dietary recommendations.

METHODS

Subjects were randomly assigned to receive a placebo (n=32) or gemfibrozil (1200 mg/day) (n=32).

RESULTS

In both placebo and gemfibrozil treated groups, significant reductions were noted in body weight, fat mass, waist circumference and visceral adipose tissue area measured by computed tomography (0.0001<P<0.05). Plasma cholesterol (CHOL) and apolipoprotein B (apo B) levels were also decreased in both groups (P<0.01) whereas plasma high density lipoprotein (HDL) and HDL-3-CHOL levels were only significantly (P<0.01) increased in the gemfibrozil-treated group. After the 6 month treatment period, gemfibrozil-treated men displayed significantly lower plasma triglycerides (TG) levels, compared to those who received the placebo (P<0.01). Finally, both fasting plasma insulin concentration and insulin area measured during an oral glucose load were significantly decreased only in the placebo group (P<0.05). Taken together, these results suggest that the improvement in plasma lipid/lipoprotein profile observed in gemfibrozil treated visceral obese men seems to be independent from changes in adipose tissue mass and in visceral fat accumulation. Furthermore, improvements in the plasma lipoprotein profile produced by gemfibrozil therapy appear to be independent from changes in indices of plasma glucose-insulin homeostasis.

Authors+Show Affiliations

Physical Activity Sciences Laboratory, Division of Kinesiology, Department of Social and Preventive Medicine, Faculty of Medicine, Laval University, Québec, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11477498

Citation

Dumont, M, et al. "Effect of a Six Month Gemfibrozil Treatment and Dietary Recommendations On the Metabolic Risk Profile of Visceral Obese Men." International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity, vol. 25, no. 8, 2001, pp. 1136-43.
Dumont M, Mauriège P, Bergeron J, et al. Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. Int J Obes Relat Metab Disord. 2001;25(8):1136-43.
Dumont, M., Mauriège, P., Bergeron, J., Després, J. P., & Prud'homme, D. (2001). Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity, 25(8), 1136-43.
Dumont M, et al. Effect of a Six Month Gemfibrozil Treatment and Dietary Recommendations On the Metabolic Risk Profile of Visceral Obese Men. Int J Obes Relat Metab Disord. 2001;25(8):1136-43. PubMed PMID: 11477498.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. AU - Dumont,M, AU - Mauriège,P, AU - Bergeron,J, AU - Després,J P, AU - Prud'homme,D, PY - 2000/07/19/received PY - 2001/01/03/revised PY - 2001/02/06/accepted PY - 2001/7/31/pubmed PY - 2002/1/5/medline PY - 2001/7/31/entrez SP - 1136 EP - 43 JF - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity JO - Int J Obes Relat Metab Disord VL - 25 IS - 8 N2 - OBJECTIVE: The aim of the present study was to investigate the effects of a 6 month gemfibrozil treatment. SUBJECTS: A sample of 64 visceral obese men (age 46+/-6 y; body mass index 31+/-3 kg/m(2); waist circumference 104+/-7 cm; mean+/-s.d.) who received dietary recommendations. METHODS: Subjects were randomly assigned to receive a placebo (n=32) or gemfibrozil (1200 mg/day) (n=32). RESULTS: In both placebo and gemfibrozil treated groups, significant reductions were noted in body weight, fat mass, waist circumference and visceral adipose tissue area measured by computed tomography (0.0001<P<0.05). Plasma cholesterol (CHOL) and apolipoprotein B (apo B) levels were also decreased in both groups (P<0.01) whereas plasma high density lipoprotein (HDL) and HDL-3-CHOL levels were only significantly (P<0.01) increased in the gemfibrozil-treated group. After the 6 month treatment period, gemfibrozil-treated men displayed significantly lower plasma triglycerides (TG) levels, compared to those who received the placebo (P<0.01). Finally, both fasting plasma insulin concentration and insulin area measured during an oral glucose load were significantly decreased only in the placebo group (P<0.05). Taken together, these results suggest that the improvement in plasma lipid/lipoprotein profile observed in gemfibrozil treated visceral obese men seems to be independent from changes in adipose tissue mass and in visceral fat accumulation. Furthermore, improvements in the plasma lipoprotein profile produced by gemfibrozil therapy appear to be independent from changes in indices of plasma glucose-insulin homeostasis. UR - https://www.unboundmedicine.com/medline/citation/11477498/Effect_of_a_six_month_gemfibrozil_treatment_and_dietary_recommendations_on_the_metabolic_risk_profile_of_visceral_obese_men_ L2 - https://medlineplus.gov/cholesterolmedicines.html DB - PRIME DP - Unbound Medicine ER -